Lee S. Schwartzberg, MD, FACP
Recent advancements in the field of breast cancer are reshaping the treatment paradigm for subsets of patients with the disease, bringing new therapies and strategies into focus, according to experts who participated in an OncLive Peer Exchange®
“I think the science in breast cancer is really making tangible differences in our patients’ lives now and that’s exciting,” said Lee S. Schwartzberg, MD.
Hormone-Driven Breast Cancer
Three CDK4/6 inhibitors are now approved for patients with metastatic, HR-positive, HER2- negative breast cancer. Palbociclib (Ibrance) was the first agent approved in this drug class in 2015, followed by abemaciclib (Verzenio) and ribociclib (Kisqali) in 2017. These therapies have been targeted for postmenopausal women.
... to read the full story